20192019

Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Lugtenburg, P. J., Zijlstra, J. M., Doorduijn, J. K., Böhmer, L. H., Hoogendoorn, M., Berenschot, H. W., Beeker, A., van der Burg-de Graauw, N. C., Schouten, H. C., Bilgin, Y. M., Kersten, M-J., Koene, H. R., Herbers, A. H. E., de Jong, D., Hijmering, N., Lam, K. H., Chiţu, D., Brouwer, R. E., van Imhoff, G. W. & the Dutch HOVON group, 1 Nov 2019, In : British Journal of Haematology. 187, 3, p. 347-355 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access